Although CDK4/6 is believed to play a critical role in cancer proliferation, CDK4/6 inhibitors have very modest single-agent activity in cancer, possibly due to partial compensation by cyclin E/CDK2 in the absence of CDK4/6 (58–60). Here, CDK4 is linked to cancer.